Problems in Postmenopausal Women
|
|
- Lawrence Cummings
- 6 years ago
- Views:
Transcription
1 Menopausal Management: Where are we in 27? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms Genital atrophy Decrease in skin collagen Rapid bone loss Increase in coronary heart disease Increase in Alzheimer s disease Benefits of Menopausal HT: What We Thought We Knew before WHI Prevents or abolishes hot flashes Prevents or improves genital atrophy Prevents or slows bone loss Reduces risk of cardiovascular disease Improves cerebral blood flow May reduce risk of Alzheimer s disease May reduce risk of colon cancer Improves overall quality of life 1
2 Risks of Menopausal HT: What We Thought We Knew before WHI Breast cancer,?rr Endometrial cancer, RR (unopposed estrogen) Venous thromboembolism 2 additional cases per 1, women Low mortality rate of 1% Gall bladder disease Menopausal HT/CVD Why we thought we knew it Observational studies (e.g. Nurse s Health Study) suggested ET/HT use associated with 5% reduction in CHD (Mikkola et al., Ann Med, 24) The NIH Lipid Research Clinics Trial Reported that ET normalized CHD risk for women with a CHD history (Bush et al., Circulation, 1987) Angiographic studies suggested that women with the Most Severe CHD derived the Most Benefit from ET/HT (Sullivan et al, Arch Int Med, 199) Clinical Studies Observational studies Retrospective Cohort (Prospective) Double-blind, randomized, placebocontrolled trials Publication of Clinical Trials in July, 22 Heart & Estrogen/Progestin Replacement Study (HERS) II JAMA 22;288:49-66 (July 3) Women s Health Initiative (WHI) JAMA 22;288: (July 17) 2
3 HERS Trial: Clinical Outcomes Outcome Total mortality Nonfatal and fatal MI CABG Percutaneous revascularization Stroke / TIA Venous thromboembolism Gallbladder disease All cancers Breast cancer RR (95% CI) 1.8 ( ).99 ( ).87 ( ).95 ( ) 1.13 ( ) 2.89 ( ) 1.38 ( ) 1.12 ( ) 1.3 ( ) HERS: Conclusion HRT should not be used to reduce the risk of further CHD events in postmenopausal women with already established CHD Hulley S, et al. JAMA. 1998;28(7): Additional Supporting Cardiovascular Studies In the Women s Angiographic Vitamin and Estrogen (WAVE) trial, neither hormone therapy nor antioxidant vitamins provided any CV benefit to menopausal women with angiographic evidence of CHD, and potential for harm was suggested (Waters et al., JAMA 22;288:2432). The British ESPRIT (EStrogen in the Prevention of ReInfarction Trial), which randomly assigned menopausal women 5 to 69 who were heart attack survivors to estradiol vs. placebo, found no reduction in the overall risk of further cardiac events, reinfarction or cardiac death at 24 mos with hormone therapy (Lancet 22;36:21). Estrogen Replacement and Atherosclerosis (ERA) Study 39 women with documented coronary artery stenosis (mean age, 65 years) randomization Herrington et al, N Engl J Med, 2 Placebo n = 15 CEE only (.625 mg) n = 1 CEE (.625 mg) + MPA (2.5 mg) n = 14 Postmenopausal women with >3% coronary artery stenosis Mean follow-up 3.2 years Angiographic follow-up in 248 patients Mean cholesterol 216 mg/dl Compliance: 86% placebo, 84% HT, 74% ET 3
4 Change in diameter (mm) ERA Study Change in Minimal Lumen Diameter Placebo CEE CEE+MPA Modified from Herrington et al, N Engl J Med, 2 Progression of atherosclerosis Women s Health Initiative (WHI) Study design: Subjects: Interventions: Randomized, double-blind, placebocontrolled, primary prevention trial ET 1,739 surgically menopausal women HT 16,68 naturally postmenopausal women Both were 5 to 79 years old (mean age, 63.3 years) ET CEE.625 mg HT CEE.625 mg + MPA 2.5 mg daily or placebo 1 end point: Nonfatal MI or CHD death Time frame: Planned 8.5 years; terminated at 5.2 years Writing Group for the Women's Health Initiative Investigators, JAMA, 22 WHI HRT Study Cardiovascular Events (Cumulative) WHI HRT Study Disease Rates for Women on Estrogen + Progestin vs Placebo Cumulative Hazard Coronary Heart Disease Stroke Pulmonary Embolism 3% HR, % Cl, % 1% % HR, % Cl, 1.7-2% % % HR, % Cl, % 1% Number of Cases/year in 1, Women Risks Benefits Neutral Estrogen +Progestin Placebo Placebo Estrogen + Progestin CHD Stroke Breast Cancer PE Colorectal Cancer Hip Fracture Endometril Deaths Cancer HR: hazard ratio; Cl, confidence interval Writing Group for the Women s Health Initiative. JAMA. 22;288: Writing Group for the Women s Health Initiative. JAMA. 22;288:
5 Number of women needing to take HT for one extra adverse or protective event per year: 11 for myocardial infarction 12 for stroke 6 for serious thromboembolism 13 for invasive breast cancer 2 to prevent a hip fracture 17 to prevent a colon cancer Observations about the WHI Study 97.5% of subjects had no adverse events Subjects not as healthy as thought at entry, i.e., not well designed as a primary prevention trial The WHI Estrogen-Alone Trial (JAMA 24:291: ) Only strokes and hip fractures were significantly impacted in 1,739 postmenopausal women aged 5-79 over 6.8 years: There was an absolute excess risk of 12 additional strokes and 6 fewer hip fractures per 1, person-years. A possible reduction in breast cancer risk, inconsistent with other studies, requires further investigation. Reconciling observational studies and clinical trials Preliminary analyses suggest lower hazard ratios (for CVD) in women aged 5 to 59 years. Menopausal women should be reassured that estrogen remains a viable treatment option for the treatment of symptoms of estrogen deficiency. 5
6 What s different? WHI vs. Observational studies Methodological explanations: Confounding intrinsic biases of observational studies Incomplete capture of early clinical events attenuation of risk Biological explanations Clinical characteristics of the populations timing of initiation of treatment Characteristics of hormone therapy type and dosage Manson JE, et al. 26; 13:139 WHI vs. Observational studies Biological explanations Clinical characteristics of the populations timing of initiation of treatment Characteristics of hormone therapy type and dosage Mean age 63 BMI 28.5 kg/m 2 Past User 2% Current User 6% WHI HRT Study: Patient Characteristics Never User 74% % of Enrolled Population N=5522 N= Age N=3576 Hormone Use Prior to Study Entry 6
7 The Effect of Body Mass on the Risk of CHD: Putting the WHI Results in Perspective RH for CVD >29 BMI (kg/m 2 ) WHI* *Mean BMI 28.5 kg/m 2. BMI data from Willett et al, JAMA, 1995 WHI data from Writing Group for the Women s Health Initiative Investigators, JAMA, RH for CVD Inflammatory Biomarkers, HT, and Coronary Heart Disease (CHD) in the WHI (Pradhan et al., JAMA 22;288:98) Median baseline levels of CRP and interleukin-6 (IL-6) were significantly higher in 34 women with incident CHD than in matched controls Both inflammatory markers were associated with a 2-fold increase in odds for CHD events HT use increased CRP but not IL-6 Use or non-use of HRT had less importance as a predictor of cardiovascular risk than did baseline levels of either CRP or IL-6 Age-Adjusted Relative Risk of Future Cardiovascular Events According to C-Reactive Protein Quintile at Baseline Among Postmenopausal Women That Were Nonusers (n=15,745) and Users (n=12,139) of HT Non HRT Users HRT Users Baseline Quintile of C-Reactive Protein Modified from Ridker et al, N Engl J Med, 22 Comparison of C-Reactive Protein Increases of Postmenopausal Women Treated with Oral CEE or Transdermal 2 E (Mean change ± 95% Confidence Interval) Change from Baseline in CRP Concentrations (%) Oral CEE Transdermal 2 E Oral CEE Transdermal 2 E 6 mos 12 mos Modified from Decensi et al, Circulation, 22 7
8 Adventitia Media Internal Elastic Lamina Fatty Streak/Plaque Fibrous Cap Plaque Necrotic Core VASCULAR BIOLOGIST'S DEFINITION OF PRIMARY PREVENTION Fibrous Cap Plaque CARDIOLOGIST'S DEFINITION OF MMP-9 PRIMARY PREVENTION Event Adventitia Media Internal Elastic Lamina Estrogen Effects on the Natural History of Atherosclerosis Fatty Streak/Plaque Fibrous Cap Plaque Estrogen Effects in Atherogenesis LDL oxidation LDL atherogenicity LDL binding/accum lesion progression CAMs monocyte adhesion/ macrophage accumulation SMC proliferation lesion progression Endothelial function vasodilation Benefits of estrogen on atherosclerosis prevention Fibrous Cap Plaque Necrotic Core Fibrous Cap Plaque Necrotic Core MMP-9 Estrogen Effects in Established Plaques Inflammation PQ instability lesion progression MMP expression PQ instability/rupture Neovascularization PQ hemorrhage Loss of Estrogen Benefits Expression of estrogen receptors Vascular responsivity Potentially adverse effects of estrogen on atherosclerosis/chd Effect of ET and HT on CHD in Postmenopausal Women Age Years Since Menopause < Hazard Ratio for CHD (ET Arm*) Hazard Ratio for CHD (HT Arm**) *The Women s Health Initiative Steering Committee, JAMA, 24 **Manson et al, N Engl J Med, 23 Metalloproteinase and Gelatinolytic Activity of Human Coronary Artery Atherosclerotic Plaques From Galis et al, J Clin Invest,
9 Plasma Expression of Matrix Metalloproteinase-9 (MMP-9) and Gelatinolytic Activity of Postmenopausal Women (Av. Age 66 yrs) Treated Either with Placebo or HT (.625 mg CEE and 2.5 mg MPA per day) 8 p=.2 p=.36 2 Effect of Statin Treatment on Plasma MMP-9 of Patients with Coronary Heart Disease MMP-9 (ng/ml) Gelatinolytic Activity (densitometric units) Plasma MMP-9 (ng/ml) Placebo HT Placebo HT Modified from Zanger et al, J Am Coll Cardiol, 2 Prudent Diet From Koh et al, Cor Artery Dis, 21 Prudent Diet + Simvastatin Effects of Statins on Early CVD Events in HERS Effect of Statins on CHD Among HT Users in WHI Incidence (%) With CEE/MPA With Placebo No Statin Use Statin Use Statin Use Yes No Hazard Ratio for CHD Follow-up (years) Manson et al, N Engl J Med, 23 Herrington et al, Circulation, 22 9
10 Patient Characteristics: Age Grodstein et al. J Womens Health 26 Nurse s Health Study: evaluating time from menopause women near menopause reduced CV risk (RR.66 CI:.54-.8) Manson et al. NEJM 27 WHI: coronary calcium women 5-59, coronary calcium score lower in women on ET vs. placebo (OR.69 CI: ) Patient Characteristics: Age 27 Hydroxycholesterol SERM Competitive inhibitor of the estrogen receptor Accumulates in vessels in low estrogenic state Umetani et al. Nature Med 27 27HC inhibition of vasoprotective effect of estrogen Age In Years HYPOTHETICAL RATIONALE FOR KEEPS Early Intervention (KEEPS) MHT No MHT Adventitia Media Internal Elastic Lamina Fatty Streak/Plaque Fibrous Cap Plaque Late Intervention (HERS, WHI) 5 1 Years Post- menopause Necrotic Core MHT MMP-9 >65 15 Umetani et al. Nature Med 27 1
11 ELITE Trial Early vs. Late Hodis FN (Los Angeles, CA) Drug Effect of 17β-estradiol Primary endpoint Carotid IMT Timing Perimenopausal women > 6 years post menopausal The Menopausal Syndrome Almost all signs and symptoms result from decreased circulating estrogen Symptoms: Hot flushes, paresthesias, cold hands and feet, headache, vertigo, irritability, anxiety, nervousness, depression, fatigue, weight gain, insomnia, night sweats, forgetfulness Signs: Depressed menstrual bleeding, relocation of fat deposits, decreased skin elasticity, osteoporosis in 25%, genital tract atrophy Some signs and symptoms may begin long before menopause HRT/ET and Neuroprotection WHIMS (Shumaker et al., JAMA 23;289: ; Rapp et al., JAMA 23;289: ) increased cognitive impairment and dementia in the oldest population Observational/animal studies role of timing, type improvement in certain skills (memory and verbal fluency) impact of smoking role of oxidative stress, inflammation HRT/ET and Neuroprotection Impact of timing Suzuki et al. PNAS 27 Mouse model Estradiol exerted a profound neuroprotective action when administered immediately upon ovariectomy (attenuating proinflammatory cytokines) Benefit lost is given remote from ovariectomy 11
12 Estradiol and Depressive Disorders (Soares et al., Arch Gen Psychiatry 21;58:529) 5 perimenopausal women aged 4-55 with irregular menstrual periods and FSH > 25 IU/L meeting criteria for major depressive, dysthymic, or minor depressive disorder by DSM-IV blindly randomized to transdermal estradiol (.1 mg) or placebo for 12 wks Remission of depression observed in 17 of 25 (68%) on E 2 and 5% on placebo Regardless of DSM-IV diagnosis, subjects responded similarly to E 2 Estrogen, Menopause, and the Aging Brain: How basic neuroscience can inform hormone therapy in women HT/ET at the menopausal transition and afterward could have beneficial effects on neurological symptoms Disconnect with WHI and WHIMS Animal and pre-clinical data supporting benefit Timing of treatment Administration formulations Morrison, Brinton, Schmidt, Gore: J Neuroscience: 26:1332 Risks of Menopausal HT: What We Think We Know Now Breast cancer RR (all forms of estrogen) increased with progestogen (especially continuous) Endometrial cancer R (unopposed estrogen) reduced by progestin Venous Thromboembolism (oral therapy) 2 additional cases per 1, Mortality low, 1% Gall bladder disease CVD increased risk with existing disease and remote from menopause Risk of Invasive Breast Cancer by Duration of ET Use Among All Postmenopausal Women Who Had Undergone Hysterectomy and Those With ER+/PR+ Cancers Only* Copyright restrictions may apply. Chen, W. Y. et al. Arch Intern Med 26;166:
13 Estrogen and Breast Cancer Breast Cancer Reanalysis Lancet, 1997:35:147 Current/recent use HT: 2.3%/year Delay in menopause: 2.8%/year Does the Route of Estrogen Therapy Affect the Risk of Venous Thromboembolism (VTE)? (Scarabin et al., Lancet 23;362:428) Multicenter, case-control study of women of mean age 62 yr from France 155 cases of first VTE and 381 matched controls Overall 32 (21%) cases and 27 (7%) controls were current users of oral estrogen, whereas 3 (19%) cases and 93 (24%) controls were current users of transdermal estrogen After adjustment the odds ratio in current users of estrogen was 3.5 for oral and.9 for transdermal, respectively a 4-fold greater risk for oral compared to transdermal Menopausal Hormone Therapy and Osteoporosis Estrogen and estrogen/progestin are indicated for prevention of osteoporosis only. Yet the WHI is the first study not specifically designed with fracture as a primary endpoint to document a decrease in fractures. Cumulative Hazard for Hip Fracture WHI Results: Effect of HRT on Risk of Hip Fracture Kaplan-Meier Estimate HR =.66 95% ncl = % aci = Time (year) Placebo HRT HR = hazard ratio; nci = nominal confidence interval; aci = adjusted confidence interval. Writing Group for the Women s Health Initiative Investigators. JAMA. 22;288:
14 JAMA 26; 295:257 JAMA 26; 295:257 Menopause 25; 12:18 14
15 Suvanto-Luukkonen, et al. Obstet Gynecol 26; 18:41 Reddy SY, et al. Reddy SY, et al. 15
16 Current Truths Regarding Menopausal HT and CVD The public is largely unaware that CVD is the primary cause of mortality in women. Women should not take estrogen to prevent CVD. Women with known CVD should not begin HT for treatment of heart disease. Current Truths Regarding HRT and CVD (cont.) A statin is the drug of choice for any woman with hypercholesterolemia. In selecting HT, consideration should be given to the lipid profile because different HT regimens have different effects on various lipoproteins. First-line therapies for women with known CVD include risk factor modifications, aspirin, β- blockers, statins, and angiotensin-converting enzyme inhibitors, just as in men. Benefits of Menopausal HT: What We Think We Know Now Prevents or abolishes hot flashes Prevents or improves genital atrophy Prevents or slows bone loss May reduce risk of Alzheimer s disease May reduce risk of colon cancer May improve overall quality of life Alternatives and Future Directions for Research Estrogen Therapy progestagen-iud for uterine protection transdermal estrogen Raloxifene no change in CRP lowers homocysteine increased VTE Tibolone decrease in MMP-9 decrease in PAI-1 New SERMs Neurospecific action Bone specific action 16
17 So Just When Is Menopausal HT Indicated Now? For symptomatic women For prevention of osteoporosis in those where other drugs may be contraindicated?in women with new onset depression?for those who feel better taking estrogen 17
Conflict of Interest. Problems in Peri- Postmenopausal Women. Hormone Replacement Therapy Where are we in /27/2011
Hormone Replacement Therapy Where are we in 2011 Conflict of Interest Financial conflict none Research conflict Funded research: Kronos Early Estrogen Progestin Study (KEEPS) Marcelle I. Cedars, M.D. Professor
More informationProblems in Postmenopausal Women. Case 1. Menopausal Management: Where are we in 2010? 10/29/2010
Menopausal Management: Where are we in 21? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms
More informationProblems in Postmenopausal Women
Menopausal Management: Where are we in 29? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms
More informationConflict of Interest. Problems in Peri- Postmenopausal Women. Management of Menopause 10/24/2014. Financial conflict none Research conflict
Conflict of Interest Management of Menopause Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Financial conflict none Research conflict Funded
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationMenopausal Management: What Has Changed?
Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning
More informationHeart Disease in Women: Is it Really Different?
Heart Disease in Women: Is it Really Different? Jennifer Jarbeau, MD Southcoast Physicians Group Cardiovascular Associates of RI Disclosures I have no financial interests to disclose I wish I did! Are
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationMenopausal Hormone Therapy
V FORUM on WOMEN, HEALTH, and GENDER Madrid, October 14-15, 2008 Menopausal Hormone Therapy The Women s Health Initiative (WHI) randomized, placebo-controlled trials Marcia L. Stefanick, Ph.D. Professor
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationPreventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004
Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004 I am also PRO!... because HT does not increase breast cancer, and overall, its benefits out weight
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationCardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal
Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal JoAnn E. Manson, MD, DrPH, FAHA Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine i and dthe Michael
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationHow HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
More information9/27/2017. Disclosure. Selecting Progestogens: Breast, Cardiovascular, and Cognitive Outcomes. James H Liu, MD. Overview
Disclosure Selecting Progestogens: Breast, Cardiovascular, and Cognitive utcomes James H Liu, MD Arthur H Bill Professor and Chair Departments of Reproductive Biology and bstetrics and Gynecology UH Cleveland
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationOVERVIEW WOMEN S HEALTH: YEAR IN REVIEW
OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through
More informationFor more than 50 million American women, and millions
AHA Science Advisory Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Lori Mosca, MD, PhD; Peter Collins, MD; David M.
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationTHE WOMEN S HEALTH INITIAtive
ORIGINAL CONTRIBUTION JAMA-EXPRESS Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women s Health Initiative Randomized Controlled Trial Writing
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationSex, hormones and the heart
Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationThe view of The International Menopause Society on the Women s Health Initiative
CLIMACTERIC 2002;5:211 216 The view of The International Menopause Society on the Women s Health Initiative H. P. G., President of the International Menopause Society on behalf of the Executive Committee
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationS. Savonitto*, D. Colombo, F. Prati
12_12 03/02/17 14.14 Pagina 79 Coronary artery disease after menopause and the role of estrogen replacement therapy S. Savonitto*, D. Colombo, F. Prati * manzoni hospital, lecco. Clinical pharmacology,
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationSomething has changed? The literature from 2008 to present?
Something has changed? The literature from 2008 to present? Elina Hemminki National Institute for Health and Welfare, Helsinki, Finland Rome Oct 7, 2011: Post-menopausal hormone therapy and women's information
More informationStatins are the most commonly used medications for
UPDATES ON AGING The Timing Hypothesis and Hormone Replacement Therapy: A Paradigm Shift in the Primary Prevention of Coronary Heart Disease in Women. Part 1: Comparison of Therapeutic Efficacy Howard
More informationCardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital
Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital Death By Cause - Women 2004 UK Death by Cause-Women 2004 UK -CVD is responsible
More informationNatural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationPharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure
Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting 2015 Disclosure The faculty and planners for this activity, as well as the CME staff, do not have any relevant
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationHormone replacement therapy in postmenopausal women
The American Journal of Surgery 188 (2004) 136 149 Review Hormone replacement therapy in postmenopausal women Edgar D. Staren, M.D., Ph.D., M.B.A.*, Shuab Omer, M.D. Department of Surgery, Medical College
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationWOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS OVERVIEW BUT NOT. TOPICS 8/14/2009. Judith Walsh, MD, MPH Professor of Medicine UCSF
WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS Judith Walsh, MD, MPH Professor of Medicine UCSF OVERVIEW Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More information